NovaTears®
First-in-class, preservative-free eye treatment and
tear film stabilizer in evaporative dry eye disease
tear film stabilizer in evaporative dry eye disease

As the first-of-its kind, NovaTears® offers a new Mode of Action by acting as a lubricating lipid layer stabilizer and evaporative barrier for improving tear film stability and quality.
NovaTears® is clinically validated by significant improvement in signs and symptoms in evaporative dry eye disease and MGD patients (4 clinical trials).
What are the benefits of NovaTears®?
- prevents evaporation
- no blurring – same refractive index as water
- excellent spreading properties on the eye
- long duration
- preservative-free
- small drops size ~ 10µl
- silky feeling
What is the regulatory status of NovaTears®?
- In Europe the product is registered as CE-marked product under the medical device directive.
- In New Zealand and Australia, NovaTears® has received registrational approval as medical device in October 2017.
- In the USA, we are pursuing a New Drug Application (NDA) for NovaTears® with the next important milestone: a confirmatory phase 3 study starting in 2019.
- In Japan, we have received the classification of NovaTears® as Medical Device from PMDA and will submit the approval dossier following a clinical study in Japan.
In which countries are NovaTears® available?
- Europe CE-approved as EvoTears® by Ursapharm
- Australia/NewZealand by AFT Pharmaceuticals
Are you interested in a collaborating with Novaliq?